Supported signals
What the available public evidence supports strongly enough to carry into the next diligence step.
Target Triage Brief · One target · Five working days
Ascendo reviews the public evidence around one target and shows what is supported, what conflicts, what remains unknown and what should be verified next — so your internal decision can be made with clearer boundaries.
The decision output
The useful question is not whether more information can be collected. It is whether the current case deserves more attention, which claims can survive scrutiny and what would materially change the view.
What the available public evidence supports strongly enough to carry into the next diligence step.
Where the target narrative conflicts with external signals or extends beyond what can currently be demonstrated.
What cannot be resolved from public evidence and should remain an explicit diligence question.
A bounded recommendation to proceed, verify first, revisit later, or deprioritize — with the reasoning shown.
Good fit
Scope boundary
The five-day clock starts after the target, decision question, scope and payment handling are confirmed.
You send the target, the current thesis, the decision stage and the question that matters most.
Ascendo reviews public sources, timing signals, operating context, obvious constraints and contradictory evidence.
You receive the evidence state, proof gaps, next diligence questions and recommended posture within five working days of confirmed scope.
Proof standard
The open CEE Agritech intelligence package is not a sample Target Triage Brief. It is a broader proof asset showing the source discipline, claim separation and explicit uncertainty used across Ascendo work.
Inspect the evidence standard →The first email should contain only the target, decision context and high-level question. Do not include confidential financials, code names, seller material or personal data before handling is agreed.
NDA and confidential-handling paths are available when the case requires them.
A Target Triage Brief is a fixed-scope, five-working-day independent evidence review of one acquisition target. It helps a searcher or investment team decide whether the case deserves the next phase of attention and diligence.
The fixed 900 EUR price covers one named target, a confirmed decision question, review of relevant public evidence, a compact written brief, source links, proof gaps, and recommended next diligence questions.
No. The brief is an early, bounded outside view based primarily on public evidence. It is not full commercial, financial, legal, tax, technical, or management due diligence and is not investment advice or a valuation opinion.
Start with a sanitized outline. If sensitive information is necessary, confidential handling or an NDA path can be agreed before the material is shared.
The brief marks the boundary explicitly. Unresolved questions become a focused primary-intelligence or next-diligence list rather than being filled with unsupported conclusions.
Send a sanitized outline first. Scope, the five-day start date, payment and any confidential handling are confirmed before work begins.